We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+4.23%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2.4B
AUM Growth
+$2.4B
Cap. Flow
+$169M
Cap. Flow %
7.05%
Top 10 Hldgs %
44.25%
Holding
367
New
126
Increased
77
Reduced
66
Closed
85

Top Buys

Rank Stock Value
1
TPST icon
Tempest Therapeutics
TPST
+$94.4M
2
IWM icon
iShares Russell 2000 ETF
IWM
+$24M
3
AGN
Allergan plc
AGN
+$13.8M
4
ZGNX
Zogenix, Inc.
ZGNX
+$11.9M
5
MBLY
Mobileye N.V.
MBLY
+$8.8M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$42.1M
2
GILD icon
Gilead Sciences
GILD
+$11.5M
3
ACHN
Achillion Pharmaceuticals
ACHN
+$11.1M
4
A icon
Agilent Technologies
A
+$6.68M
5
ADVM
Adverum Biotechnologies
ADVM
+$3.71M

Sector Composition

Rank Sector Weight
1 Healthcare 9.36%
2 Technology 0.55%
3 Energy 0.39%
4 Industrials 0.16%
5 Financials 0.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DHR icon
51
CALL
Danaher
DHR
$140B
$8.49M 0.35%
1,488
– –
DHR icon
52
PUT
Danaher
DHR
$140B
$8.49M 0.35%
1,488
– –
LUMO
53
PUT
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$8.18M 0.34%
+166
New +$64.3K
RCPT
54
CALL
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$7.92M 0.33%
480
+350
+269% +$44.3K
MNKD icon
55
CALL
MannKind Corp
MNKD
$1.21B
$7.28M 0.3%
2,801
+507
+22% +$15.3K
TLT icon
56
iShares 20+ Year Treasury Bond ETF
TLT
$43.1B
$7.23M 0.3%
+55,320
New +$7.22M
HCA icon
57
CALL
HCA Healthcare
HCA
$92.8B
$7.05M 0.29%
937
+745
+388% +$53.5K
THC icon
58
CALL
Tenet Healthcare
THC
$22.6B
$7.01M 0.29%
1,415
+1,265
+843% +$59.1K
CEMP
59
DELISTED
Cempra, Inc.
CEMP
$6.88M 0.29%
+200,400
New +$6.03M
DERM
60
DELISTED
Dermira, Inc.
DERM
$6.77M 0.28%
385,185
+33,097
+9% +$556K
MNKD icon
61
MannKind Corp
MNKD
$1.21B
$6.57M 0.27%
252,690
+80,540
+47% +$2.43M
PRGO icon
62
CALL
Perrigo
PRGO
$1.43B
$6.46M 0.27%
390
+103
+36% +$16.4K
BMRN icon
63
PUT
BioMarin Pharmaceuticals
BMRN
$12B
$6.34M 0.26%
+509
New +$53.9K
HZNP
64
CALL
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$6.31M 0.26%
2,429
+1,843
+315% +$33.8K
BCLI
65
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
$6.27M 0.26%
+93,969
New +$5.94M
CELG
66
PUT
DELISTED
Celgene Corp
CELG
$5.51M 0.23%
478
+408
+583% +$48.8K
ENDP
67
CALL
DELISTED
Endo International plc
ENDP
$5.39M 0.22%
601
+348
+138% +$29.1K
BLCM
68
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$5.36M 0.22%
23,152
-10,000
-30% -$2.42M
ACHN
69
CALL
DELISTED
Achillion Pharmaceuticals
ACHN
$5.36M 0.22%
5,439
+2,720
+100% +$34K
DHR icon
70
Danaher
DHR
$140B
$5.3M 0.22%
92,920
+11,010
+13% +$632K
NVAX icon
71
PUT
Novavax
NVAX
$1.21B
$5.15M 0.21%
+311
New +$50.5K
NBIX icon
72
CALL
Neurocrine Biosciences
NBIX
$18.4B
$5.12M 0.21%
1,288
-305
-19% -$10.9K
LXRX icon
73
Lexicon Pharmaceuticals
LXRX
$1.04B
$5.07M 0.21%
767,400
+738,443
+2,550% +$5.04M
HALO icon
74
CALL
Halozyme
HALO
$9.9B
$5M 0.21%
+3,502
New +$50.5K
BLUE
75
PUT
DELISTED
bluebird bio
BLUE
$4.92M 0.2%
+31
New +$40.9K
1 2
3
4 5

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q1 2015 Portfolio in Review

As of Q1 2015, Sabby Management held 367 positions worth $2.4B, up 75,773% from $3.17M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Sabby Management deployed $169M of net new capital in Q1 2015, opening 126 new positions and adding to 77 existing holdings. Its largest new stake was Tempest Therapeutics: 709 shares worth $4.69M.

By sector, the portfolio is most concentrated in Healthcare at 9.4% of assets, up from 9.2% a quarter earlier, followed by Technology and Energy.

On the sell side, the largest reduction was Achillion Pharmaceuticals, an estimated $11.1M trimmed.

  • Sabby Management's largest Q1 2015 buy was Tempest Therapeutics: 709 shares worth $4.69M.
  • Sabby Management added most to Allergan plc in Q1 2015, an estimated $13.8M increase.
  • Sabby Management's biggest Q1 2015 reduction was Achillion Pharmaceuticals, cutting an estimated $11.1M.
  • Sabby Management fully exited Pfizer in Q1 2015, selling an estimated $42.1M.
  • Sabby Management's ten largest holdings make up 44% of its $2.4B portfolio in Q1 2015.
  • Sabby Management opened 126 new positions and closed 85 in Q1 2015.
  • Sabby Management's portfolio value rose 75,773% quarter-over-quarter to $2.4B.

Based on Sabby Management's 13F filing for Q1 2015, filed 15 May 2015.